NEC led a $150m Series B round in BostonGene.

NEC, a Japanese multinational information technology and electronics corporation, led a $150m Series B round in BostonGene, a provider of biomedical software, with participation from Impact Investment Capital and Japan Industrial Partners. "Many academic and community oncologists across the United States have already adopted BostonGene’s Molecular Portrait Test to improve their patients’ quality of care. NEC recently launched a healthcare and life science business unit that utilizes AI and other digital technologies as a key initiative within our 2025 Mid-term Management Plan. We are thrilled to expand on our strategic partnership with BostonGene to advance how physicians treat their patients and dramatically improve clinical outcomes in the US, Japan, and the rest of the world," Takayuki Morita, NEC President and CEO.